|Daily Range||$36.09 - $36.40|
|52-Week Range||$32.68 - $38.71|
|Dividend (Yield)||$0.00 (2.6%)|
|Average Daily Volume||1,906,515|
|Current FY EPS||$1.97|
These value stocks may be hitting a new 52-week low, but they may not be there for long!
Falling markets may be creating an opportunity to pick up these three biotechnology companies at discount prices.
Cancer is among the scariest diagnoses. These 15 statistics speak to both the seriousness of the disease and the progress that's being made fighting it.
These may be cheap biotech stocks, but they may not be cheap for long according to the three analysts we asked.
Lung cancer is estimated to have claimed 160,000 lives in the U.S. in 2013, and it's particularly common in these 10 states. Find out what's being done to improve patients' quality of life and overall survival in lieu of this terrible disease.
Prescription drug costs in Switzerland are more than 40% lower than the U.S. on a per capita basis, yet the Swiss government is looking to lower those costs even further. Find out what benefits and risks could await its approach.
It's the leader in a fast-growing young industry, but does Illumina (ILMN) have what it takes to trounce the market over the long term?
Breast cancer was diagnosed in more than 220,000 women in 2011. Find out in which five states a breast cancer diagnosis is the most common, as well as what current and developing therapies are being used to treat this terrible disease.
While investors need to wait to hear how Organovo's liver assays sell, the company is giving us a taste of the future.
While the S&P Biotech index soars, ImmunoGen shareholders are getting left in the dust. Find out what's been holding shares back in 2014, and whether or not ImmunoGen will rebound from its current price.